Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.33 USD
Change Today +3.07 / 17.79%
Volume 2.8M
ADXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 7:40 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Key Developments

Advaxis, Inc. - Special Call

To review recent accomplishments and key near-term milestones of the company

Advaxis, Inc. Submits Special Protocol Assessment Request to the U.S. Food and Drug Administration to Initiate Detailed Design Discussions for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer

Advaxis, Inc. announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) to initiate detailed design discussions for a Phase 3 clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer (HRLACC). The Phase 3 trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation, Inc. and to be led by principal investigator Thomas Herzog, M.D., Professor of Obstetrics & Gynecology and Clinical Director at the University of Cincinnati Cancer Institute, Cincinnati, Ohio. The SPA request includes specific questions from Advaxis to facilitate a meaningful dialog with the FDA on the proposed study design. Following receipt, the FDA will determine the appropriateness of the SPA request and may take up to 45 calendar days to provide comments to Advaxis. The nature and extent of comments received will determine the need for additional rounds of review and/or a formal meeting. The FDA's assessment of the SPA request, and all related valuable feedback, will aid to inform the development of ADXS-HPV in locally advanced cervical cancer. The proposed Phase 3 clinical trial (AIM2CERV) is designed as an adequate and well-controlled double-blind, placebo-controlled multinational study of ADXS-HPV (ADXS11-001) administered in the adjuvant setting following concurrent chemoradiation given with curative intent in patients with HRLACC for whom recurrence has not yet occurred. Advaxis plans to initiate the Phase 3 trial by the end of 2015.

Advaxis, Inc. Announces Results from Clinical Study of ADXS-HER2

Advaxis, Inc. announced that results from an ongoing clinical study of ADXS-HER2 in canine osteosarcoma (OSA). Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Of the 12 canine patients recruited to date, seven are alive with current survival times ranging from 66 to 479 days. The median survival time of dogs receiving palliative radiation plus ADXS-HER2 has not been reached. The median time to progression of these 12 canine patients is 238 days. The reported median survival time for historical control dogs with OSA that do not undergo amputation but instead receive the same palliative radiation protocol without ADXS-HER2 is 136 days. Data from the first Phase 1 clinical trial in canine OSA were presented last year during the 2014 ACVIM Forum, which showed ADXS-HER2 is able to delay or prevent metastatic disease and significantly prolong overall survival in canines with OSA that had minimal residual disease following standard of care (amputation and follow-up chemotherapy). At the time of the presentation, two-thirds of the treated canine patients were still alive and therefore a median survival time had not been reached. Conversely, historical control dogs that underwent standard of care and did not receive ADXS-HER2 had a median survival time of 316 days. Advaxis licensed ADXS-HER2 to Aratana Therapeutics in March of 2014 for pet health indications and it is now being developed and prepared for commercialization using the name AT-014. Advaxis and Aratana anticipate conditional licensure of AT-014 for the treatment of canine OSA from the U.S. Department of Agriculture (USDA) in 2016. Translating Canine Clinical Research into Human Trials were the canine evidence with ADXS-HER2 may have important translational relevance for human patients with OSA and other HER2+ cancers, such as breast, gastric and esophageal. Advaxis expects to initiate a Phase 1b dose-escalation study of ADXS-HER2 in humans with HER2+ solid tumors in mid-2015. Once dosing is established in the human trial, Advaxis plans to work with Children's Oncology Group (COG) to launch a pivotal trial in human pediatric OSA in early 2016. HER2 is expressed in approximately 40-60% of pediatric and canine OSA and in pulmonary metastatic disease, suggesting that immune targeting of HER2 might delay or eliminate metastatic disease. The hypothesis warrants investigation and will be tested in the pivotal pediatric OSA trial. HER2 expression is associated with more aggressive disease, increased risk of relapse and decreased overall survival.

Advaxis Inc. Announces FDA Clearance of IND Application for Phase 2 Study of ADXS-HPV

Advaxis Inc. announced the clearance of the Investigational New Drug or IND application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corp.'s investigational oral indoleamine 2,3-dioxygenase 1 or IDO1 inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.

Advaxis, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM

Advaxis, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Daniel J. O'Connor, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $20.33 USD +3.07

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $23.43 USD +1.43
Eurocine Vaccines AB kr1.90 SEK -0.06
Genocea Biosciences Inc $13.73 USD +0.78
GenVec Inc $2.04 USD +0.19
Inovio Pharmaceuticals Inc $8.16 USD +0.17
View Industry Companies
 

Industry Analysis

ADXS

Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.